Litcius/Paper detail

Biomarkers for the Clinical Diagnosis of Alzheimer’s Disease: Metabolomics Analysis of Brain Tissue and Blood

Yangyang Wang, Yanping Sun, Yumeng Luo, Donghui Peng, Xiao Li, Bing‐You Yang, Qiuhong Wang, Haixue Kuang

2021Frontiers in Pharmacology26 citationsDOIOpen Access PDF

Abstract

With an increase in aging populations worldwide, age-related diseases such as Alzheimer's disease (AD) have become a global concern. At present, a cure for neurodegenerative disease is lacking. There is an urgent need for a biomarker that can facilitate the diagnosis, classification, prognosis, and treatment response of AD. The recent emergence of highly sensitive mass-spectrometry platforms and high-throughput technology can be employed to discover and catalog vast datasets of small metabolites, which respond to changed status in the body. Metabolomics analysis provides hope for a better understanding of AD as well as the subsequent identification and analysis of metabolites. Here, we review the state-of-the-art emerging candidate biomarkers for AD.

Topics & Concepts

MetabolomicsDiseaseBiomarker discoveryBiomarkerIdentification (biology)MedicineAlzheimer's diseaseComputational biologyBioinformaticsDiagnostic biomarkerProteomicsBiologyPathologyBotanyBiochemistryGeneMetabolomics and Mass Spectrometry StudiesAlzheimer's disease research and treatmentsTryptophan and brain disorders
Biomarkers for the Clinical Diagnosis of Alzheimer’s Disease: Metabolomics Analysis of Brain Tissue and Blood | Litcius